Switzerland nears deal to get Moderna COVID vaccine, official says
Reuters
Published Aug 05, 2020 03:51AM ET
ZURICH (Reuters) - Switzerland is close to signing a deal to secure access for a coronavirus vaccine being developed by Moderna (NASDAQ:MRNA) of the U.S., a government official has said.
Switzerland will soon sign a reservation and supply deal, Pascal Strupler, the director of the Federal Office of Public Health, told the Swiss TV programme Club late on Tuesday.
"We are only a few hours away from completing a purchase contract. With this contract we will get it very quickly," Strupler said.
He declined to give financial details of any deal.
If the vaccine passes trials and is authorised for use, it could be produced in Switzerland under a deal between drugmaker Lonza and Moderna.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.